Levine Cancer Institute
Welcome,         Profile    Billing    Logout  
 2 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahtani, Reshma
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
11/26
05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Recruiting
2
40
US
Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta
Adrienne G. Waks, Gilead Sciences
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
11/26
11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Terminated
2
52
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer
Breast Cancer, Triple Negative Breast Cancer
10/24
12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Reyes, Stephanie
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
NCT07031219: HIV/HBV/HCV Triple Screening in Primary Care

Not yet recruiting
N/A
50
US
provider order set/order panel
University of Texas Southwestern Medical Center, Gilead Sciences
HIV, HBV (Hepatitis B Virus), HCV
12/27
12/27
NCT05995574: Avatar Contraception Communication Training

Not yet recruiting
N/A
166
US
avatar communication training
University of Texas Southwestern Medical Center
Communication
06/30
06/30
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mahtani, Reshma
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
SERIES, NCT06263543: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC

Recruiting
2
75
US
Sacituzumab govitecan, Trodelvy
Reshma L. Mahtani, D.O., Gilead Sciences
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
06/26
12/26
ATEMPT 2.0, NCT04893109: Adjuvant T-DM1 vs TH

Recruiting
2
500
US
trastuzumab-emtansine, T-DM1, Kadcyla, Trastuzumab SC, Herceptin Hylecta, Paclitaxel, Taxol, Onxal
Dana-Farber Cancer Institute, Genentech, Inc.
Breast Cancer, HER2-positive Breast Cancer
11/26
05/28
NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Recruiting
2
40
US
Sacituzumab Govitecan, Trodelvy, Trastuzumab, Herceptin, Trastuzumab and Hyaluronidase-oysk, Herceptin Hylecta
Adrienne G. Waks, Gilead Sciences
Her 2 Positive Breast Cancer, Breast Cancer Female, Breast Cancer Metastatic
11/26
11/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Terminated
2
52
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer
Breast Cancer, Triple Negative Breast Cancer
10/24
12/24
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Reyes, Stephanie
NCT06377852: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Recruiting
3
500
US
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
American Society of Clinical Oncology, Patient-Centered Outcomes Research Institute
Metastatic Breast Cancer
08/28
09/28
NCT07031219: HIV/HBV/HCV Triple Screening in Primary Care

Not yet recruiting
N/A
50
US
provider order set/order panel
University of Texas Southwestern Medical Center, Gilead Sciences
HIV, HBV (Hepatitis B Virus), HCV
12/27
12/27
NCT05995574: Avatar Contraception Communication Training

Not yet recruiting
N/A
166
US
avatar communication training
University of Texas Southwestern Medical Center
Communication
06/30
06/30
MelMarT-II, NCT03860883: Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Recruiting
N/A
2998
Europe, Canada, US, RoW
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Melanoma and Skin Cancer Trials Limited, Norfolk and Norwich University Hospitals NHS Foundation Trust, Canadian Cancer Trials Group, Cancer Trials Ireland, Zuyderland Medical Centre
Cutaneous Melanoma, Stage II
12/29
12/34

Download Options